Search Results
Pirtobrutinib: The next generation of BTK inhibitors
Tolerability of next-generation BTK inhibitors: acalabrutinib, zanubrutinib and pirtobrutinib
The role of next-generation BTK inhibitors in the treatment of CLL
The benefits of next-generation BTK inhibitors in CLL
The pharmacokinetics of pirtobrutinib
Next-Generation BTK inhibitors and their role in the CLL treatment landscape
Updated results from the BRUIN study: pirtobrutinib in the treatment of MCL
Genomic evolution & resistance to pirtobrutinib in covalent BTK inhibitor pre-treated CLL
Second-generation BTK inhibitors and their clinical impact
Pirtobrutinib for BTK inhibitor-naïve and BTK inhibitor pre-treated R/R MCL
Phase I/II BRUIN study: pirtobrutinib in patients intolerant to a covalent BTK inhibitor
Updates from the BRUIN study – long-term safety of pirtobrutinib in R/R MCL
